nafamostat has been researched along with Arrhythmia in 1 studies
nafamostat: inhibitor of trypsin, plasmin, pancreatic kallikrein, plasma kallikrein & thrombin; strongly inhibits esterolytic activities of C1r & C1 esterase complement-mediated hemolysis; antineoplastic
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Uchino, S | 1 |
| Bellomo, R | 1 |
| Morimatsu, H | 1 |
| Morgera, S | 1 |
| Schetz, M | 1 |
| Tan, I | 1 |
| Bouman, C | 1 |
| Macedo, E | 1 |
| Gibney, N | 1 |
| Tolwani, A | 1 |
| Oudemans-van Straaten, H | 1 |
| Ronco, C | 1 |
| Kellum, JA | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| PrEvalence of Acute and Chronic Kidney Disease Treated by Renal Replacement Therapy in the ICU Environment[NCT02341885] | 2,000 participants (Actual) | Observational | 2015-03-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 other study available for nafamostat and Arrhythmia
| Article | Year |
|---|---|
Continuous renal replacement therapy: a worldwide practice survey. The beginning and ending supportive therapy for the kidney (B.E.S.T. kidney) investigators.
Topics: Acute Kidney Injury; Aged; Anticoagulants; Arrhythmias, Cardiac; Benzamidines; Citrates; Drug Utiliz | 2007 |